249 related articles for article (PubMed ID: 28704094)
1. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
2. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome.
Y-Hassan S; Falhammar H
Endocrine; 2019 Sep; 65(3):483-493. PubMed ID: 31399912
[TBL] [Abstract][Full Text] [Related]
3. Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A; Glinicki P; Gietka-Czernel M
Front Endocrinol (Lausanne); 2023; 14():1204851. PubMed ID: 37522121
[TBL] [Abstract][Full Text] [Related]
4. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma.
Giavarini A; Chedid A; Bobrie G; Plouin PF; Hagège A; Amar L
Heart; 2013 Oct; 99(19):1438-44. PubMed ID: 23837998
[TBL] [Abstract][Full Text] [Related]
5. Acute cardiac complications and subclinical myocardial injuries associated with pheochromocytoma and paraganglioma.
Zhou J; Xuan H; Miao Y; Hu J; Dai Y
BMC Cardiovasc Disord; 2021 Apr; 21(1):203. PubMed ID: 33882857
[TBL] [Abstract][Full Text] [Related]
6. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
[TBL] [Abstract][Full Text] [Related]
8. Takotsubo-like cardiomyopathy in pheochromocytoma.
Agarwal V; Kant G; Hans N; Messerli FH
Int J Cardiol; 2011 Dec; 153(3):241-8. PubMed ID: 21474192
[TBL] [Abstract][Full Text] [Related]
9. Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma.
Zhang L; Åkerström T; Mollazadegan K; Beuschlein F; Pacak K; Skogseid B; Crona J
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37185155
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study.
Ebbehoj A; Stochholm K; Jacobsen SF; Trolle C; Jepsen P; Robaczyk MG; Rasmussen ÅK; Feldt-Rasmussen U; Thomsen RW; Søndergaard E; Poulsen PL
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2251-e2261. PubMed ID: 33479747
[TBL] [Abstract][Full Text] [Related]
11. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review.
Batisse-Lignier M; Pereira B; Motreff P; Pierrard R; Burnot C; Vorilhon C; Maqdasy S; Roche B; Desbiez F; Clerfond G; Citron B; Lusson JR; Tauveron I; Eschalier R
Medicine (Baltimore); 2015 Dec; 94(50):e2198. PubMed ID: 26683930
[TBL] [Abstract][Full Text] [Related]
12. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease.
Ogasawara T; Fujii Y; Kakiuchi N; Shiozawa Y; Sakamoto R; Ogawa Y; Ootani K; Ito E; Tanaka T; Watanabe K; Yoshida Y; Kimura N; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S
J Clin Endocrinol Metab; 2022 Aug; 107(9):2545-2555. PubMed ID: 35730597
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.
Lopez C; Bima C; Bollati M; Bioletto F; Procopio M; Arata S; Candela DG; Beccuti G; Ghigo E; Maccario M; Parasiliti-Caprino M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982228
[TBL] [Abstract][Full Text] [Related]
14. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
[TBL] [Abstract][Full Text] [Related]
15. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
16. Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma.
Wang Y; Yu X; Huang Y
Front Endocrinol (Lausanne); 2022; 13():853878. PubMed ID: 35355563
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.
Hamidi O; Young WF; Gruber L; Smestad J; Yan Q; Ponce OJ; Prokop L; Murad MH; Bancos I
Clin Endocrinol (Oxf); 2017 Nov; 87(5):440-450. PubMed ID: 28746746
[TBL] [Abstract][Full Text] [Related]
18. Coronary artery myointimal dysplasia in patients with pheochromocytoma-possible causal relationship: pathophysiology and clinical implication with reference to Takotsubo cardiomyopathy and spontaneous coronary dissection.
Chow LTC; Chow MBCY
Cardiovasc Pathol; 2018; 37():45-53. PubMed ID: 30342321
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
[TBL] [Abstract][Full Text] [Related]
20. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]